日本時間2021年8月6日 9:00 AMより (2時間程度)
Zoom によるWeb Meeting形式で実施します。開始5分前に入室可能となります。


第一部 (英語、1時間35分程度)
  1. 司会からの連絡(司会:David Lane / AIFAM Group)
  2. 開催のあいさつ
    学校法人北里研究所 理事長 小林弘祐
  3. 研究発表(Moderator :Sanjay Mitta / AIFAM Group)
  4. 第一部閉会のあいさつ
    学校法人北里研究所 常任理事 渋谷明隆
第二部 (日本語、20分程度)
  1. Webパーティールーム(Moderator :Takuma Aoyama / AIFAM Group)
    発表者の皆さん並びにご希望される視聴者の方々に専用ルーム(Breakout Room)にお入りいただき、ご挨拶や意見交換をしていただきます。(10分程度)
  2. 表彰・講評
    Takashi Kiyoizumi, M.D., Ph.D., SM / TBAP Advisor


  1. 菅谷公伸 (University of Central Florida / Progenicyte Japan社)
  2. 結城一郎 (University of California Irvine / AquaTex社)
  3. 小久保謙一 (北里大学医療衛生学部 / Physiologas Technologies社)
  4. 松井英則 (北里大学大村智記念研究所)
  5. 宮﨑和雄 (MiCAN Technologies社)
  6. 福山 隆 (北里大学メディカルセンター)
  7. 内山洋介 (北里大学理学部)


TBAP Advisors

Takashi Kiyoizumi, MD, PhD, SM
Mr. Takashi Kiyoizumi is a life science entrepreneur and executive with over 30 years of experience as well as a board certified plastic surgeon. As a founding President and CEO of MediciNova, he raised over $190 million in private placements and a successful IPO, within 5 years of inception. Prior to founding MediciNova, he was President and CEO of Tanabe Research Laboratories, USA (U.S. affiliate of Mitsubishi Tanabe Pharma). Since 2005, he has been an active angel investor/board member with various life science ventures in San Diego.
  • M.D. and Ph.D. from Keio University School of Medicine
  • MBA from Sloan School of Management at MIT
Sadashi Suzuki, MBA
Mr. Suzuki started his 40+ yrs career in healthcare/life sciences with Kyowa Hakko. Recently, he held a series of management positions at Japan divisions of global companies, Baxter Japan, Alcon Japan, and Affymetrix Japan (CEO), Bio-Rad Laboratories Japan (CEO),Cepheid Japan,(CEO). Currently, he is the head of the Japan office of Newton Biocapital (Belgium base VC). He has extensive experience working with Japanese regulatory authorities on securing the approval of medical devices, testing equipment, reagents and compounds.
  • MBA from Kellogg School at Northwestern Univ.

Corporate Members

Yoshiharu Mizui, Ph.D.
President of Eisai Innovation, Inc. & Head of Cambridge office

Yoshiharu Mizui founded Eisai Innovation, Inc. in 2019. Prior to that he was a global head of the BD/Strategy Department in Oncology Business Group at Eisai from 2016-2019. He was also a founding member of H3 Biomedicine and lead the oncology program from 2011-2016. He has more than 20 years of experience as a discovery research biologist. He received his Ph.D. from Kyushu University.
Fumitaka Mori, Ph.D.
Partner at Taiho Innovations, LLC

Mr. Mori is a senior member of Taiho Innovations, which focuses on seed to early stage investments and company creation, following 5 years of venture investments at Remiges Ventures Boston. Prior to his experience in Venture Capital firm, he has over 12 years of experience in drug discovery research, strategic research planning, research alliances and portfolio strategy at Taiho Pharmaceutical. He received his Ph.D. in Clinical Pharmaceutical Sciences from the University of Shizuoka.
Sadakazu Miyashita, MS
Mr. Miyashita is presently Director of Corporate Venture Investment with Eisai Co, Ltd. Prior to this, he held roles in corporate strategy with a focus on business development as well as being stationed in Andover, MA where he was head of Portfolio Management of Andover Innovation Medicines. While at Andover, he assumed executive responsibility for drug discovery research through direct collaborations with peer laboratories involved in early stage pharmaceutical development. Before that, he has 15 years of experience as a biologist in drug discovery research along with management rolls related to strategic planning in Eisai’s laboratories. Mr. Miyashita received his MS in Molecular Biology from Gifu Pharmaceutical University.
Kiyoshi Tanigawa, PhD
President / Managing Partner at Taiho Innovations, LLC

Mr. Tanigawa is a founding member of Taiho Innovations,LLC, focusing on seed to early stage biotech investments and venture creation based on innovative academia seeds in Japan. Prior to that he was venture partner at Remiges Venture, a US-Japan cross-border venture capital firm investing in therapeutics. He has more than 25 years of experience in healthcare industry including drug discovery, clinical development, corporate strategy, product portfolio management, market forecast and new business development. He received his Ph.D. from Kyushu University.

Special Guests

Justin Klein, MD, JD
Justin Klein, MD, JD is a co-founder and Managing Partner at Vensana Capital. Justin was previously a partner and leader of the medical technology investing practice at NEA, one of the largest and most active venture capital firms in the world. Justin also worked at the Duke University Health System where his experience included roles in strategy, finance and operations as Duke built one of the nation’s first integrated healthcare delivery systems. Justin currently serves as a member of the Board of Directors of the Medical Device Manufacturers Association and that of AdvaMed Accel, where he is the Chair of its MedTech Investment Working Group. Justin graduated with an AB in Economics, a BS in Biological Anthropology & Anatomy, and a Minor in Chemistry from Duke University. He also concurrently earned his MD from the Duke University School of Medicine and his JD from Harvard Law School.
Marc Martin-Casas, PhD
Marc joined Illumina Accelerator in 2019, where he manages seed investments and venture development in the genomic and precision medicine spaces. Previously, Marc led Biotech Connection – Bay Area, an incorporated nonprofit that accelerates innovation and development for biotech startups and big pharma by bringing together academic scientists, entrepreneurs, and investors. Prior to that, Marc was on the investment team at Lam Research Capital, where he sourced and performed diligence on life science investment opportunities. Marc earned his Ph.D. in Computational Biology from the University of California, Berkeley, where he focused on the development of novel tools to characterize, model, and predict heterogeneous behavior in cell populations and other complex biochemical systems.
お問い合わせ先:TBAP事務局 岡野